Biomarker subtype analysis was performed for NRG1 and ERBB3 in 108 tumor samples (89%; 51/59 in the duligotuzumab arm and 57/62 in the cetuximab arm), both potential indicators of HER3 activity. The gene discussed is ERBB3; the disease is neoplasm.